FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045794737> ?p ?o ?g. }

• W2045794737 endingPage "38" @default.
• W2045794737 startingPage "16" @default.
• W2045794737 abstract "Cardiovascular Drug ReviewsVolume 17, Issue 1 p. 16-38 Free Access CGS 30440: A Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 David S. Cohen, Corresponding Author David S. Cohen Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USAAddress correspondence and reprint requests to David S. Cohen, Novartis Institute for Biomedical Research. Novartis Pharmaceuticals Corporation, Summit, NJ 07901, U.S.A.Search for more papers by this authorCynthia A. Fink, Cynthia A. Fink Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorAngelo J. Trapani, Angelo J. Trapani Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorRandy L. Webb, Randy L. Webb Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorPatricia A. Zane, Patricia A. Zane Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorRicardo E. Chatelain, Ricardo E. Chatelain Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this author David S. Cohen, Corresponding Author David S. Cohen Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USAAddress correspondence and reprint requests to David S. Cohen, Novartis Institute for Biomedical Research. Novartis Pharmaceuticals Corporation, Summit, NJ 07901, U.S.A.Search for more papers by this authorCynthia A. Fink, Cynthia A. Fink Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorAngelo J. Trapani, Angelo J. Trapani Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorRandy L. Webb, Randy L. Webb Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorPatricia A. Zane, Patricia A. Zane Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this authorRicardo E. Chatelain, Ricardo E. Chatelain Novartis Institute for Biomedical Research, Novartis Pharmaceuticals Corporation, Summit, NJ, USASearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3466.1999.tb00002.xCitations: 7AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Abassi Z, Haramati A, Hoffman A, Burnett JC Jr, Winaver J. Effect of converting-enzyme inhibition on renal reponse to ANF in rats with experimental heart failure. Am J Physiol 1990; 259: R84– R89. 2 Anand IS, Kalra GS, Ferrari R, Wahi PL, Harris PC, Poole-Wilson PA. Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. Int J Cardiol 1990; 28: 341– 346. 3 Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612– 619. 4 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993– 2000. 5 Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992; 41: 891– 897. 6 Bayliss J, Canepa-Anson R, Norell M, Poole-Wilson P, Sutton G. The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin. Eur Heart J 1986; 7: 877– 884. 7 Bevan EG, Cornell JMC, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10: 607– 613. 8 Bhagwat SS, Fink CA, Gude C, et al. α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1995; 5: 735– 738. 9 Bohacek R, De Lombaert S, McMartin C, Priestle J, Grutter M. Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors. J Am Chem Soc 1996; 118: 8231– 8249. 10 Camargo MJ, von Lutterotti N, Campbell WG Jr, et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11: 31– 40. 11 Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988; 11: 239– 243. 12 Chatelain RE, Ghai RD, Trapani AJ, et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998; 284: 974– 982. 13 Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362– 1374. 14 Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998; 32: 87– 95. 15 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429– 1435. 16 Cushman DW, Cheung HW. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20: 1637– 1648. 17 de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89– 94. 18 Deen WM, Maddox DA, Robertson CR, Brenner BM. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. Am J Physiol 1974; 227: 556– 562. 19 Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808– 814. 20 Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39: 1112– 1117. 21 Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995; 13: 797– 804. 22 Fink CA, Carlson JE, McTaggert PA, et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1996; 39: 3158– 3168. 23 Fink CA, Qiao Y, Berry C, Sakane Y, Ghai R, Trapani A. New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24. 11. J Med Chem 1995; 38: 5023– 5030. 24 Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22: 305– 313. 25 Fournié-Zaluski MC, Coric P, Turcaud S, et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 1994; 37: 1070– 1083. 26 Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 1981; 2: 543– 547. 27 Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991– 995. 28 Gros C, Noel N, Souque A, et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991; 88: 4210– 4214. 29 Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979; 59: 137– 164. 30 Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85– F93. 31 Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40: 195– 202. 32 Janssen WMT, de Zeeuw D, van der Hem GK, de Jong PE. Antihypertensive effect of a 5 d infusion of atrial natriuretic factor in humans. Hypertension 1989; 13: 640– 646. 33 Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46– 55. 34 Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEES Lett 1988; 232: 1– 8. 35 Kohzuki M, Hodsman GP, Johnston CI. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol 1989; 256: H533– H538. 36 Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass, Circ Res 1989; 65: 640– 646. 37 Lee RW, Raya TE, Michael U, Foster S, Meeks T, Goldman S. Captopril and ANP: changes in renal hemodynamics, glomerular-ANP receptors and guanylate cyclase activity in rats with heart failure. J Pharmacol Exp Ther 1992; 260: 349– 354. 38 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456– 1462. 39 Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989; 11: 1325– 1350. 40 Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991; 88: 1636– 1642. 41 Monopoli A, Ongini E, Cigola E, Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20: 496– 504. 42 Natsume T, Kardon MB, Pegram BL, Frohlich ED. Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass. Cardiovasc Drugs Ther 1989; 3: 433– 439. 43 O'Connell JE, Jardine AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10: 271– 277. 44 Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994; 7: 943– 947. 45 Olins GM, Kreiter PA, Trapani AJ, Spear KL, Bovy PR. Specific inhibitors of endopetidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol Cell Endocrinol 1989; 61: 201– 208. 46 Orlowski M, Wilk S. Purification and specificity of a membrane bound metalloendoprotease from bovine pituitary. Biochemistry 1981; 20: 4942– 950. 47 Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987; 9: 178– 187. 48 Pelayo JC, Quan AH, Shanley PF. Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiol 1990; 258: F414– F422. 49 Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669– 677. 50 Pfeffer MA, Greaves SC, Arnold MO, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. Circulation 1997; 95: 2643– 2651. 51 Pham I, Gonzalez W, el Amrani AI, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265: 1339– 1347. 52 Podjarny E, Rathaus M, Bernheim J, et al. Captopril, but not diltiazem, favorably affects the course of early chronic renal disease. Nephron 1990; 55: 196– 202. 53 Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991; 65: 249– 255. 54 Richards AM, Crozier IG, Espiner EA, et al. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 1992; 20: 735– 741. 55 Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993; 22: 231– 236. 56 Richards AM, Crozier IG, Kosoglou T, et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993; 22: 119– 126. 57 Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993; 11: 407– 416. 58 Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 2: 709– 711. 59 Robl JA, Sun C-Q, Stevenson J, et al. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused hetero-cyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997; 40: 1570– 1577. 60 Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR. In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1996; 28: 672– 678. 61 Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993; 266: 872– 883. 62 Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991; 17: 456– 165. 63 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1991; 327: 685– 691. 64 Stier CT Jr, Benter IF, Ahmad S, et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13: 115– 121. 65 Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991; 4: 680– 687. 66 Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16: 452– 461. 67 Trapani AJ, Smits JFM, Sun XJ, Webb RL, Yau ET. CGS 24128: a long-acting inhibitor of neutral endopeptidase 3.4.24.11. Cardiovasc Drug Rev 1994; 12: 271– 285. 68 Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993; 267: 108– 116. 69 Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 1995; 272: 619– 627. 70 Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995; 275: 745– 752. 71 Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal and high renin experimental hypertension. Am J Hypertens 1998; 11: 363– 372. 72 Ura N, Carretero OA, Erdos EG. Role of renal endopeptidase-24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32: 507– 514. 73 Vacher E, Fornes P, Domerque V, Richer C, Bruneval P, Giudicelli JF. Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993; 6: 951– 959. 74 Villarreal D, Freeman RH, Johnson RA. Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure. Am J Physiol 1992; 262: R509– R516. 75 Webb RL, Abramson ML, Beil ME, Odorico LM, Chatelain RE. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997; 30: 632– 642. 76 Webb RL, Barclay BW, Navarrete AE, Wosu NJ, Sahota P. Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 775– 793. 77 Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992; 20: 233– 241. 78 Wiemer G, Scholkens BA, Becker RH, Busse R. Ramaprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558– 563. 79 Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res 1994; 28: 209– 214. Citing Literature Volume17, Issue1March 1999Pages 16-38 ReferencesRelatedInformation" @default.
• W2045794737 created "2016-06-24" @default.
• W2045794737 creator A5003084736 @default.
• W2045794737 creator A5026429928 @default.
• W2045794737 creator A5065799721 @default.
• W2045794737 creator A5065822345 @default.
• W2045794737 creator A5073039017 @default.
• W2045794737 creator A5079589473 @default.
• W2045794737 date "2006-06-07" @default.
• W2045794737 modified "2023-09-26" @default.
• W2045794737 title "CGS 30440: A Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11" @default.
• W2045794737 cites W1843089250 @default.
• W2045794737 cites W1967932178 @default.
• W2045794737 cites W1971379814 @default.
• W2045794737 cites W1973034165 @default.
• W2045794737 cites W1980029715 @default.
• W2045794737 cites W1981339359 @default.
• W2045794737 cites W1987000855 @default.
• W2045794737 cites W1996249113 @default.
• W2045794737 cites W2014092855 @default.
• W2045794737 cites W2014241928 @default.
• W2045794737 cites W2014351702 @default.
• W2045794737 cites W2024667090 @default.
• W2045794737 cites W2025802158 @default.
• W2045794737 cites W2031534703 @default.
• W2045794737 cites W2032827384 @default.
• W2045794737 cites W2042711802 @default.
• W2045794737 cites W2047651173 @default.
• W2045794737 cites W2051837586 @default.
• W2045794737 cites W2052097767 @default.
• W2045794737 cites W2052680288 @default.
• W2045794737 cites W2053181724 @default.
• W2045794737 cites W2055696770 @default.
• W2045794737 cites W2057249082 @default.
• W2045794737 cites W2060843858 @default.
• W2045794737 cites W2063928700 @default.
• W2045794737 cites W2064549490 @default.
• W2045794737 cites W2065793802 @default.
• W2045794737 cites W2067023576 @default.
• W2045794737 cites W2069691833 @default.
• W2045794737 cites W2073074562 @default.
• W2045794737 cites W2075098122 @default.
• W2045794737 cites W2077258054 @default.
• W2045794737 cites W2080254721 @default.
• W2045794737 cites W2082415380 @default.
• W2045794737 cites W2082526293 @default.
• W2045794737 cites W2083547867 @default.
• W2045794737 cites W2086868114 @default.
• W2045794737 cites W2087313530 @default.
• W2045794737 cites W2092389955 @default.
• W2045794737 cites W2099601233 @default.
• W2045794737 cites W2102044876 @default.
• W2045794737 cites W2115885172 @default.
• W2045794737 cites W2118846428 @default.
• W2045794737 cites W2120909576 @default.
• W2045794737 cites W2126857247 @default.
• W2045794737 cites W2126871516 @default.
• W2045794737 cites W2127502023 @default.
• W2045794737 cites W2128903833 @default.
• W2045794737 cites W2141740436 @default.
• W2045794737 cites W2158528618 @default.
• W2045794737 cites W2160458644 @default.
• W2045794737 cites W2168029143 @default.
• W2045794737 cites W2185679486 @default.
• W2045794737 cites W2312388685 @default.
• W2045794737 cites W2315972959 @default.
• W2045794737 cites W2316814104 @default.
• W2045794737 cites W2321162261 @default.
• W2045794737 cites W2330500218 @default.
• W2045794737 cites W2398585180 @default.
• W2045794737 cites W2417467405 @default.
• W2045794737 cites W2470433031 @default.
• W2045794737 cites W2615684303 @default.
• W2045794737 cites W2952821877 @default.
• W2045794737 cites W4235409922 @default.
• W2045794737 cites W4245244523 @default.
• W2045794737 doi "https://doi.org/10.1111/j.1527-3466.1999.tb00002.x" @default.
• W2045794737 hasPublicationYear "2006" @default.
• W2045794737 type Work @default.
• W2045794737 sameAs 2045794737 @default.
• W2045794737 citedByCount "5" @default.
• W2045794737 countsByYear W20457947372012 @default.
• W2045794737 countsByYear W20457947372020 @default.
• W2045794737 crossrefType "journal-article" @default.
• W2045794737 hasAuthorship W2045794737A5003084736 @default.
• W2045794737 hasAuthorship W2045794737A5026429928 @default.
• W2045794737 hasAuthorship W2045794737A5065799721 @default.
• W2045794737 hasAuthorship W2045794737A5065822345 @default.
• W2045794737 hasAuthorship W2045794737A5073039017 @default.
• W2045794737 hasAuthorship W2045794737A5079589473 @default.
• W2045794737 hasBestOaLocation W20457947371 @default.
• W2045794737 hasConcept C104826730 @default.
• W2045794737 hasConcept C126322002 @default.
• W2045794737 hasConcept C134018914 @default.
• W2045794737 hasConcept C181199279 @default.
• W2045794737 hasConcept C185592680 @default.
• W2045794737 hasConcept C198710026 @default.
• W2045794737 hasConcept C27016395 @default.

• next